Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 85

1.

Frequency of ERG-positive prostate carcinoma in Polands.

Kaczmarczyk K, Dyduch G, Białas M, Demczuk S, Szopiński T, Chłosta P, Okoń K.

Pol J Pathol. 2013 Oct;64(3):175-9.

2.

ERG positive prostatic cancer may show a more angiogenetic phenotype.

Strzępek A, Kaczmarczyk K, Białas M, Szpor J, Dyduch G, Szopiński T, Chłosta P, Okoń K.

Pathol Res Pract. 2014 Dec;210(12):897-900. doi: 10.1016/j.prp.2014.07.009. Epub 2014 Aug 9.

PMID:
25220615
3.

Immunohistochemical expression of Ets-related gene-transcriptional factor in adenocarcinoma prostate and its correlation with Gleason score.

Mannan R, Bhasin TS, Manjari M, Singh G, Bhatia PK, Sharma S.

Indian J Pathol Microbiol. 2016 Oct-Dec;59(4):489-495. doi: 10.4103/0377-4929.191794.

4.

Foamy gland carcinoma of the prostate in needle biopsy: incidence, Gleason grade, and comparative α-methylacyl-CoA racemase vs. ERG expression.

Warrick JI, Humphrey PA.

Am J Surg Pathol. 2013 Nov;37(11):1709-14. doi: 10.1097/PAS.0b013e318293d85b.

PMID:
23797726
5.

HOXB13 G84E-related familial prostate cancers: a clinical, histologic, and molecular survey.

Smith SC, Palanisamy N, Zuhlke KA, Johnson AM, Siddiqui J, Chinnaiyan AM, Kunju LP, Cooney KA, Tomlins SA.

Am J Surg Pathol. 2014 May;38(5):615-26. doi: 10.1097/PAS.0000000000000090.

6.

Assessing the order of critical alterations in prostate cancer development and progression by IHC: further evidence that PTEN loss occurs subsequent to ERG gene fusion.

Gumuskaya B, Gurel B, Fedor H, Tan HL, Weier CA, Hicks JL, Haffner MC, Lotan TL, De Marzo AM.

Prostate Cancer Prostatic Dis. 2013 Jun;16(2):209-15. doi: 10.1038/pcan.2013.8. Epub 2013 Apr 2.

7.

Prognostic relevance of proliferation markers (Ki-67, PHH3) within the cross-relation of ERG translocation and androgen receptor expression in prostate cancer.

Goltz D, Montani M, Braun M, Perner S, Wernert N, Jung K, Dietel M, Stephan C, Kristiansen G.

Pathology. 2015 Dec;47(7):629-36. doi: 10.1097/PAT.0000000000000320.

PMID:
26517642
8.

The prognostic role of ERG immunopositivity in prostatic acinar adenocarcinoma: a study including 454 cases and review of the literature.

Xu B, Chevarie-Davis M, Chevalier S, Scarlata E, Zeizafoun N, Dragomir A, Tanguay S, Kassouf W, Aprikian A, Brimo F.

Hum Pathol. 2014 Mar;45(3):488-97. doi: 10.1016/j.humpath.2013.10.012. Epub 2013 Oct 23. Review.

PMID:
24406017
9.

ERG rearrangement is present in a subset of transition zone prostatic tumors.

Falzarano SM, Navas M, Simmerman K, Klein EA, Rubin MA, Zhou M, Magi-Galluzzi C.

Mod Pathol. 2010 Nov;23(11):1499-506. doi: 10.1038/modpathol.2010.150. Epub 2010 Aug 6.

10.

High nuclear karyopherin α 2 expression is a strong and independent predictor of biochemical recurrence in prostate cancer patients treated by radical prostatectomy.

Grupp K, Habermann M, Sirma H, Simon R, Steurer S, Hube-Magg C, Prien K, Burkhardt L, Jedrzejewska K, Salomon G, Heinzer H, Wilczak W, Kluth M, Izbicki JR, Sauter G, Minner S, Schlomm T, Tsourlakis MC.

Mod Pathol. 2014 Jan;27(1):96-106. doi: 10.1038/modpathol.2013.127. Epub 2013 Jul 26.

11.

Increased gene copy number of ERG on chromosome 21 but not TMPRSS2-ERG fusion predicts outcome in prostatic adenocarcinomas.

Toubaji A, Albadine R, Meeker AK, Isaacs WB, Lotan T, Haffner MC, Chaux A, Epstein JI, Han M, Walsh PC, Partin AW, De Marzo AM, Platz EA, Netto GJ.

Mod Pathol. 2011 Nov;24(11):1511-20. doi: 10.1038/modpathol.2011.111. Epub 2011 Jul 8.

12.

NY-ESO-1 expression is tightly linked to TMPRSS2-ERG fusion in prostate cancer.

Grupp K, Ospina-Klinck D, Tsourlakis MC, Koop C, Wilczak W, Adam M, Simon R, Sauter G, Izbicki JR, Graefen M, Huland H, Steurer S, Schlomm T, Minner S, Quaas A.

Prostate. 2014 Jul;74(10):1012-22. doi: 10.1002/pros.22816. Epub 2014 May 1.

PMID:
24789172
13.

ERG expression and prostatic adenocarcinoma.

Verdu M, Trias I, Roman R, Rodon N, Garcia-Pelaez B, Calvo M, Dominguez A, Banus JM, Puig X.

Virchows Arch. 2013 Jun;462(6):639-44. doi: 10.1007/s00428-013-1415-3. Epub 2013 May 24.

PMID:
23703293
14.

Prognostic potential of ERG (ETS-related gene) expression in prostatic adenocarcinoma.

Szász AM, Majoros A, Rosen P, Srivastava S, Dobi A, Szendrői A, Kulka J, Nyirády P.

Int Urol Nephrol. 2013 Jun;45(3):727-33. doi: 10.1007/s11255-013-0406-2. Epub 2013 May 18.

15.

The prognostic impact of high Nijmegen breakage syndrome (NBS1) gene expression in ERG-negative prostate cancers lacking PTEN deletion is driven by KPNA2 expression.

Grupp K, Boumesli R, Tsourlakis MC, Koop C, Wilczak W, Adam M, Sauter G, Simon R, Izbicki JR, Graefen M, Huland H, Steurer S, Schlomm T, Minner S, Quaas A.

Int J Cancer. 2014 Sep 15;135(6):1399-407. doi: 10.1002/ijc.28778. Epub 2014 Feb 26.

16.

Frequent TMPRSS2-ERG rearrangement in prostatic small cell carcinoma detected by fluorescence in situ hybridization: the superiority of fluorescence in situ hybridization over ERG immunohistochemistry.

Schelling LA, Williamson SR, Zhang S, Yao JL, Wang M, Huang J, Montironi R, Lopez-Beltran A, Emerson RE, Idrees MT, Osunkoya AO, Man YG, Maclennan GT, Baldridge LA, Compérat E, Cheng L.

Hum Pathol. 2013 Oct;44(10):2227-33. doi: 10.1016/j.humpath.2013.05.005. Epub 2013 Jul 12.

PMID:
23850495
17.

Immunohistochemical evaluation of TMPRSS2-ERG gene fusion in adenosis of the prostate.

Green WM, Hicks JL, De Marzo A, Illei PP, Epstein JI.

Hum Pathol. 2013 Sep;44(9):1895-901. doi: 10.1016/j.humpath.2013.02.019. Epub 2013 May 9.

PMID:
23664537
18.

ERG gene rearrangements are common in prostatic small cell carcinomas.

Lotan TL, Gupta NS, Wang W, Toubaji A, Haffner MC, Chaux A, Hicks JL, Meeker AK, Bieberich CJ, De Marzo AM, Epstein JI, Netto GJ.

Mod Pathol. 2011 Jun;24(6):820-8. doi: 10.1038/modpathol.2011.7. Epub 2011 Feb 18.

19.

ERG expression in intraductal carcinoma of the prostate: comparison with adjacent invasive prostatic adenocarcinoma.

Schneider TM, Osunkoya AO.

Mod Pathol. 2014 Aug;27(8):1174-8. doi: 10.1038/modpathol.2013.248. Epub 2014 Jan 10.

20.

Immunohistochemistry for ERG expression as a surrogate for TMPRSS2-ERG fusion detection in prostatic adenocarcinomas.

Chaux A, Albadine R, Toubaji A, Hicks J, Meeker A, Platz EA, De Marzo AM, Netto GJ.

Am J Surg Pathol. 2011 Jul;35(7):1014-20. doi: 10.1097/PAS.0b013e31821e8761.

Supplemental Content

Support Center